NASDAQ:CELC Celcuity (CELC) Stock Price, News & Analysis → Bible Shocker: Have You Seen Elon Musk’s Miracle? (From InvestorPlace) (Ad) Free CELC Stock Alerts $16.76 -0.90 (-5.10%) (As of 05/17/2024 ET) Add Compare Share Share Today's Range$16.38▼$17.6650-Day Range$15.77▼$21.6052-Week Range$8.39▼$22.19Volume230,353 shsAverage Volume224,575 shsMarket Capitalization$523.41 millionP/E RatioN/ADividend YieldN/APrice Target$29.50 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Celcuity alerts: Email Address Celcuity MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside76.0% Upside$29.50 Price TargetShort InterestBearish6.08% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.23Based on 23 Articles This WeekInsider TradingSelling Shares$10,924 Sold Last QuarterProj. Earnings GrowthDecreasingFrom ($2.85) to ($3.67) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.11 out of 5 starsMedical Sector583rd out of 920 stocksMedical Laboratories Industry13th out of 19 stocks 3.5 Analyst's Opinion Consensus RatingCelcuity has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageCelcuity has only been the subject of 4 research reports in the past 90 days.Read more about Celcuity's stock forecast and price target. Previous Next 1.0 Short Interest Percentage of Shares Shorted6.08% of the outstanding shares of Celcuity have been sold short.Short Interest Ratio / Days to CoverCelcuity has a short interest ratio ("days to cover") of 8.Change versus previous monthShort interest in Celcuity has recently increased by 2.70%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldCelcuity does not currently pay a dividend.Dividend GrowthCelcuity does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for CELC. Previous Next 2.3 News and Social Media Coverage News SentimentCelcuity has a news sentiment score of 0.23. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.42 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 23 news articles for Celcuity this week, compared to 1 article on an average week.Search Interest1 people have searched for CELC on MarketBeat in the last 30 days. MarketBeat FollowsOnly 1 people have added Celcuity to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Previous Next 4.2 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Celcuity insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $10,924.00 in company stock.Percentage Held by Insiders24.29% of the stock of Celcuity is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions63.33% of the stock of Celcuity is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Celcuity's insider trading history. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Celcuity are expected to decrease in the coming year, from ($2.85) to ($3.67) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Celcuity is -6.03, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Celcuity is -6.03, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCelcuity has a P/B Ratio of 3.92. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Celcuity's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad InvestorPlaceBible Shocker: Have You Seen Elon Musk’s Miracle?Breaking News: Elon Musk Invents New Type of A.I. (Shocking) Elon Musk is about to shock the world again with this new type of A.I.… Minting new millionaires in the process.Click here for the full story… About Celcuity Stock (NASDAQ:CELC)Celcuity Inc., a clinical stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment. Its drug candidate includes Gedatolisib, which selectively targets various class I isoforms of PI3K and mammalian target of rapamycin and focus on the treatment of patients with hormone receptor positive, HER2-negative, advanced or metastatic breast cancer, and metastatic castration resistant prostate cancer. It had a license agreement with Pfizer, Inc. for the development and commercialization rights to Gedatolisib. The company was founded in 2011 and is headquartered in Minneapolis, Minnesota.Read More CELC Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CELC Stock News HeadlinesMay 19 at 8:59 AM | americanbankingnews.comStifel Nicolaus Reaffirms "Buy" Rating for Celcuity (NASDAQ:CELC)May 19 at 6:22 AM | americanbankingnews.comCelcuity (NASDAQ:CELC) Trading Down 4.6%May 19 at 3:30 AM | americanbankingnews.comFY2028 Earnings Estimate for Celcuity Inc. (NASDAQ:CELC) Issued By HC WainwrightMay 18 at 5:36 AM | americanbankingnews.comCelcuity (NASDAQ:CELC) Stock Rating Reaffirmed by Craig HallumMay 18 at 5:36 AM | americanbankingnews.comCelcuity (NASDAQ:CELC) Rating Reiterated by HC WainwrightMay 16 at 8:02 PM | markets.businessinsider.comGrowth Potential Drives Buy Rating for Celcuity Despite Current LossesMay 16 at 8:02 PM | markets.businessinsider.comCelcuity’s Clinical and Financial Momentum Justifies Buy Rating and $24 Price TargetMay 16 at 8:02 PM | msn.comCelcuity Inc. (NASDAQ:CELC) Q1 2024 Earnings Call TranscriptMay 16 at 10:02 AM | finance.yahoo.comCelcuity Inc (CELC) (Q1 2024) Earnings Call Transcript Highlights: Navigating Challenges and ...May 15, 2024 | msn.comCelcuity Non-GAAP EPS of -$0.59May 15, 2024 | globenewswire.comCelcuity Inc. Reports First Quarter Financial Results and Provides Corporate UpdateMay 13, 2024 | americanbankingnews.comCelcuity (CELC) to Announce Quarterly Earnings on WednesdayMay 8, 2024 | globenewswire.comCelcuity Inc. Schedules Release of First Quarter 2024 Financial Results and Webcast/Conference CallMay 3, 2024 | finanznachrichten.deUSA News Group: Top Five Cancer Types Dominate New US Cases as Biotech Sector Eyes $314B Market by 2032April 28, 2024 | investing.comCelcuity director Richard E. Buller sells $5,971 in stockApril 4, 2024 | globenewswire.comCelcuity To Present at Upcoming Needham and Stifel Investor ConferencesApril 3, 2024 | msn.comCelcuity (NASDAQ:CELC): A Biotech with Blockbuster PotentialApril 3, 2024 | finance.yahoo.comCelcuity Gains 12%, Insider Trades Reap BenefitApril 1, 2024 | finance.yahoo.comCelcuity Inc. (NASDAQ:CELC) Q4 2023 Earnings Call TranscriptMarch 30, 2024 | msn.comI Gave Birth At A US Hospital In 2023 — Let's Break Down My $65,000 BillMarch 30, 2024 | msn.comOne dead, another in ICU after drug overdoseMarch 29, 2024 | markets.businessinsider.comGedatolisib’s Promising Clinical Trial Performance and Market Potential Justify Buy RatingMarch 28, 2024 | markets.businessinsider.comAnalysts Are Bullish on These Healthcare Stocks: Celcuity (CELC), Cara Therapeutics (CARA)March 28, 2024 | finance.yahoo.comQ4 2023 Celcuity Inc Earnings CallMarch 27, 2024 | finance.yahoo.comCelcuity Inc (CELC) Reports Full Year 2023 Financial Results and Highlights Key DevelopmentsSee More Headlines Receive CELC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Celcuity and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/27/2024Today5/18/2024Next Earnings (Estimated)8/08/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Medical laboratories Sub-IndustryN/A Current SymbolNASDAQ:CELC CUSIPN/A CIK1603454 Webwww.celcuity.com Phone(763) 392-0767FaxN/AEmployees55Year FoundedN/APrice Target and Rating Average Stock Price Target$29.50 High Stock Price Target$40.00 Low Stock Price Target$24.00 Potential Upside/Downside+76.0%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($2.78) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-63,780,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-61.66% Return on Assets-43.51% Debt Debt-to-Equity Ratio0.28 Current Ratio11.23 Quick Ratio13.43 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$4.28 per share Price / Book3.92Miscellaneous Outstanding Shares31,230,000Free Float23,056,000Market Cap$523.41 million OptionableOptionable Beta0.87 7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleGrowth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.Get This Free Report Key ExecutivesMr. Brian F. Sullivan (Age 62)Co-Founder, Chairman & CEO Comp: $478.12kDr. Lance G. Laing Ph.D. (Age 62)Co-Founder, Chief Science Officer, VP, Secretary & Director Comp: $389.55kMs. Vicky Hahne (Age 58)Chief Financial Officer Comp: $281.59kDr. John R. MacDonald Dabt (Age 69)Ph., Ph.D., Senior Vice President of R&D Ms. Sheri SmithActing Head of Clinical OperationsMr. Igor Gorbatchevsky M.D.Chief Medical OfficerMr. Eldon C. Mayer III (Age 63)M.B.A., Chief Commercial Officer More ExecutivesKey CompetitorsCastle BiosciencesNASDAQ:CSTLFulgent GeneticsNASDAQ:FLGTSera PrognosticsNASDAQ:SERACareDxNASDAQ:CDNABiodesixNASDAQ:BDSXView All CompetitorsInsiders & InstitutionsCalifornia State Teachers Retirement SystemSold 1,035 shares on 5/16/2024Ownership: 0.006%Baker BROS. Advisors LPBought 1,017,000 shares on 5/15/2024Ownership: 5.098%Healthcare of Ontario Pension Plan Trust FundBought 164,100 shares on 5/14/2024Ownership: 0.539%Vanguard Group Inc.Bought 7,821 shares on 5/10/2024Ownership: 2.721%SG Americas Securities LLCSold 3,154 shares on 5/7/2024Ownership: 0.021%View All Insider TransactionsView All Institutional Transactions CELC Stock Analysis - Frequently Asked Questions Should I buy or sell Celcuity stock right now? 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Celcuity in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" CELC shares. View CELC analyst ratings or view top-rated stocks. What is Celcuity's stock price target for 2024? 4 Wall Street analysts have issued 12 month price targets for Celcuity's shares. Their CELC share price targets range from $24.00 to $40.00. On average, they anticipate the company's stock price to reach $29.50 in the next year. This suggests a possible upside of 76.0% from the stock's current price. View analysts price targets for CELC or view top-rated stocks among Wall Street analysts. How have CELC shares performed in 2024? Celcuity's stock was trading at $14.57 at the beginning of 2024. Since then, CELC shares have increased by 15.0% and is now trading at $16.76. View the best growth stocks for 2024 here. When is Celcuity's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, August 8th 2024. View our CELC earnings forecast. How were Celcuity's earnings last quarter? Celcuity Inc. (NASDAQ:CELC) posted its quarterly earnings results on Wednesday, March, 27th. The company reported ($0.65) earnings per share for the quarter, topping the consensus estimate of ($0.71) by $0.06. What ETF holds Celcuity's stock? Jacob Forward ETF holds 1,688 shares of CELC stock, representing 1.01% of its portfolio. What other stocks do shareholders of Celcuity own? Based on aggregate information from My MarketBeat watchlists, some companies that other Celcuity investors own include Bank of Hawaii (BOH), InterDigital (IDCC), STAG Industrial (STAG), Evoke Pharma (EVOK), Amicus Therapeutics (FOLD), Allena Pharmaceuticals (ALNA), Genocea Biosciences (GNCA), Idera Pharmaceuticals (IDRA) and Ovid Therapeutics (OVID). When did Celcuity IPO? Celcuity (CELC) raised $18 million in an initial public offering on Wednesday, September 20th 2017. The company issued 2,000,000 shares at a price of $8.00-$10.00 per share. Craig-Hallum Capital Group served as the underwriter for the IPO. Who are Celcuity's major shareholders? Celcuity's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Baker BROS. Advisors LP (5.10%), Vanguard Group Inc. (2.72%), Healthcare of Ontario Pension Plan Trust Fund (0.54%), BNP Paribas Financial Markets (0.03%), SG Americas Securities LLC (0.02%) and California State Teachers Retirement System (0.01%). Insiders that own company stock include Brian F Sullivan, David Dalvey, Richard E Buller and Richard Nigon. View institutional ownership trends. How do I buy shares of Celcuity? Shares of CELC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:CELC) was last updated on 5/19/2024 by MarketBeat.com Staff From Our PartnersBuy this small stock before coming AI Tidal WaveChaikin AnalyticsCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill PublishingShocking $16T Elon Musk Crypto LeakCrypto 101 MediaForget Bitcoin: This $8 Stock Is the Next Big ThingBehind the MarketsDems have chosen Biden replacement?Paradigm PressHow Biden has already won 2024Porter & CompanyExposed: 10 CENT Crypto to Explode May 20th?True Market InsidersA letter is coming from the "Bureau of the Fiscal Service".Stansberry Research Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Celcuity Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.